Literature DB >> 12238917

A new, potent urotensin II receptor peptide agonist containing a Pen residue at the disulfide bridge.

Paolo Grieco1, Alfonso Carotenuto, Pietro Campiglia, Enrico Zampelli, Riccardo Patacchini, Carlo A Maggi, Ettore Novellino, Paolo Rovero.   

Abstract

Replacing Cys(5) by Pen (penicillamine, beta,beta-dimethylcysteine) in the cyclic C-terminal U-II octapeptide, U-II(4-11), we have obtained a potent urotensin II (U-II) receptor agonist. Conformational analysis of solution NMR data indicated that the putative biologically active conformation of U-II is stabilized by introduction of a Pen residue. To the best of our knowledge, this is the most potent U-II receptor agonist reported to date.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12238917     DOI: 10.1021/jm025549i

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  9 in total

1.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

Review 2.  A rat brain atlas of urotensin-II receptor expression and a review of central urotensin-II effects.

Authors:  Benjamin D Hunt; Leong L Ng; David G Lambert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-04-27       Impact factor: 3.000

3.  Optimization of RGD-Containing Cyclic Peptides against αvβ3 Integrin.

Authors:  Yan Wang; Wenwu Xiao; Yonghong Zhang; Leah Meza; Harry Tseng; Yoshikazu Takada; James B Ames; Kit S Lam
Journal:  Mol Cancer Ther       Date:  2015-12-30       Impact factor: 6.261

Review 4.  Role of urotensin II and its receptor in health and disease.

Authors:  John McDonald; Madura Batuwangala; David G Lambert
Journal:  J Anesth       Date:  2007-08-01       Impact factor: 2.078

5.  Identification and pharmacological characterization of native, functional human urotensin-II receptors in rhabdomyosarcoma cell lines.

Authors:  Stephen A Douglas; Diane Naselsky; Zhaohui Ao; Jyoti Disa; Christopher L Herold; Frank Lynch; Nambi V Aiyar
Journal:  Br J Pharmacol       Date:  2004-06-21       Impact factor: 8.739

6.  Urantide: an ultrapotent urotensin II antagonist peptide in the rat aorta.

Authors:  Riccardo Patacchini; Paolo Santicioli; Sandro Giuliani; Paolo Grieco; Ettore Novellino; Paolo Rovero; Carlo Alberto Maggi
Journal:  Br J Pharmacol       Date:  2003-12       Impact factor: 8.739

7.  Urotensin-II Ligands: An Overview from Peptide to Nonpeptide Structures.

Authors:  Francesco Merlino; Salvatore Di Maro; Ali Munaim Yousif; Michele Caraglia; Paolo Grieco
Journal:  J Amino Acids       Date:  2013-02-25

8.  Endogenous urotensin II selectively modulates erectile function through eNOS.

Authors:  Roberta d'Emmanuele di Villa Bianca; Emma Mitidieri; Ferdinando Fusco; Elena D'Aiuto; Paolo Grieco; Ettore Novellino; Ciro Imbimbo; Vincenzo Mirone; Giuseppe Cirino; Raffaella Sorrentino
Journal:  PLoS One       Date:  2012-02-02       Impact factor: 3.240

9.  A new therapeutic approach to erectile dysfunction: urotensin-II receptor high affinity agonist ligands.

Authors:  Roberta d'Emmanuele di Villa Bianca; Emma Mitidieri; Erminia Donnarumma; Ferdinando Fusco; Nicola Longo; Giuseppe De Rosa; Ettore Novellino; Paolo Grieco; Vincenzo Mirone; Giuseppe Cirino; Raffaella Sorrentino
Journal:  Asian J Androl       Date:  2015 Jan-Feb       Impact factor: 3.285

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.